Effect of Tricin on cardiomyocyte damage caused by diabetic cardiomyopathy (DCM) Authors: Rong Yu, Yaping Zhang, Tong Wang, Jinju Duan, Xiaoming Li Published: 2024 ABSTRACT AbstractObjectivesFlavonoid compounds exhibit remarkable antioxidant and anti-inflammatory properties in DCM and various other diseases. However, the specific mechanisms by which Tricin, 4’,5,7-trihydroxy-3‘,5’-dimethoxyflavone, exerts its effects in the context of DCM remain to be elucidated.MethodsRat H9C2 cells were cultured and subjected to high glucose conditions to establish a DCM cell model. Tricin was administered in varying concentrations to evaluate its effects on cellular oxidative stress markers, including ROS, LDH, and SOD. Additionally, the levels of inflammatory cytokines TNF-α, IL-1β, and IL-6, as well as the expression of TLR4, MYD88, and p-NF-κB, were assessed through ELISA and Western blotting.ResultsTricin treatment significantly ameliorated high glucose-induced oxidative stress in H9C2 cells, evidenced by reduced ROS and LDH levels and increased SOD levels in a dose-dependent manner. Furthermore, Tricin effectively suppressed the elevation of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. Tricin also inhibited the overactivation of the TLR4-MYD88-NF-κB signaling pathway, suggesting its role in modulating key inflammatory processes in DCM.ConclusionsTricin exhibits a protective role against high glucose-induced cardiac damage in a DCM cell model. By reducing oxidative stress and inflammation, and inhibiting the TLR4-MYD88-NF-κB pathway, Tricin shows significant therapeutic potential for DCM treatment. This study underscores the value of Tricin as a novel therapeutic approach for managing diabetic cardiomyopathy, warranting further research and clinical investigation.Clinical trial numberNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12872-024-04295-y.Keywords: Tricin, Diabetic cardiomyopathy, Oxidative stress, Inflammatory, TLR4/MyD88/NF-κB signaling pathway Introduction Diabetes is a prevalent chronic disease globally, affecting approximately 9.3% of the world population [1]. Diabetic cardiomyopathy (DCM), a specific form of heart disease, is a common complication of diabetes, severely impacting cardiac function and significantly increasing the risk of heart failure, thereby compromising patients’ quality of life [2]. Its etiology is primarily attributed to insulin resistance, compensatory hyperinsulinemia, and hyperglycemia in diabetic individuals, with minimal correlation to conventional cardiac risk factors [3]. Since its initial discovery in 1972, the pathogenesis of DCM has been a focal point of research interest [4]. Factors such as metabolic abnormalities, inflammatory responses, increased oxidative stress, and fibrosis may contribute to the development of DCM [5]. Therefore, investigating the pathogenesis of DCM and developing biological inhibitors and drugs to restrain its pathological processes hold significant therapeutic implications for this condition. Flavonoids are natural compounds found primarily in plants, displaying a wide range of biological activities. They are known for their significant anti-inflammatory properties and have been found effective in alleviating various conditions such as diabetes, cardiovascular diseases, cancer, and obesity [6, 7]. Studies indicate that flavonoids can protect cardiomyocytes in DCM by reducing the production of mitochondrial reactive oxygen species (ROS) and mitigating oxidative stress [8]. Tricin, chemically known as 4’,5,7-trihydroxy-3‘,5’-dimethoxyflavone, is a flavonoid compound abundant in traditional Chinese medicinal herbs such as bamboo rhizome and bamboo root [9, 10]. Both in vitro and in vivo research have confirmed the therapeutic or synergistic effects of tricin across various diseases including tumors, inflammation, diabetic retinopathy, and Parkinson’s disease, demonstrating considerable safety profiles [11, 12]. In DCM, the excessive generation of ROS leads to the release of lactate dehydrogenase (LDH) and exacerbates oxidative stress [13]. This, along with elevated levels of tumor necrosis factor α (TNF-α) and interleukin, amplifies inflammatory responses, further damaging myocardial tissue and deteriorating cardiac function [14]. Pharmacological studies have shown that Tricin exerts anti-inflammatory effects primarily by inhibiting cyclooxygenase, TNF, interleukin 6 (IL-6), and other inflammatory mediators, as well as blocking the Toll-like receptor 4 (TLR4)/NF-κB signaling cascade [15, 16]. Additionally, Tricin can mitigate oxidative stress and angiogenesis in diabetic retinopathy by inhibiting ROS production [17]. To date, there have been no studies investigating the effects of Tricin on DCM. In this study, we aimed to investigate the potential protective effects of Tricin against DCM in vitro. We utilized an established model of DCM by high glucose-induced H9C2 cells to assess the impact of Tricin on DCM pathogenesis. Specifically, we evaluated the influence of Tricin on oxidative stress, inflammatory cytokine levels, and key signaling pathways implicated in DCM progression. Our findings offer new insights into the treatment of DCM, suggesting Tricin as a promising avenue for therapeutic intervention. Materials and methods Materials Tricin used in this study was purchased from Topscience Co., Shanghai. The compound was isolated from a methanol extract of Zizania latifolia (commonly known as glutinous rice grass). The isolation process involved fractionating the extract using ethyl acetate (EtOAc), n-butanol (n-BuOH), and water (H₂O) to obtain different layers. The EtOAc layer was then subjected to multiple rounds of silica gel and ODS column chromatography to achieve purification. The isolated Tricin was characterized and confirmed through physicochemical and spectral analyses, including FT-NMR and ESI-MS, to ensure its identity and purity. Tricin was dissolved and used in dimethyl sulfoxide (DMSO). Cell culture H9C2 rat cardiomyocytes were obtained and cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Sigma, USA) and penicillin (100 U/mL) under conditions of 37 °C and 5% CO2. The H9C2 cells were seeded into 6-well plates and incubated in DMEM containing 10% FBS for 24 h. After this initial incubation, the cells were serum-starved in low-glucose DMEM for 24 h to induce a high glucose (HG)-induced H9C2 injury model. The experimental groups for H9C2 cells were as follows: (1) Control group (5.5 mM glucose), (2) HG group (150 mM glucose), (3) HG + low-dose Tricin group (Tricin 2.5 µM), (4) HG + medium-dose Tricin group (Tricin 5 µM), and (5) HG + high-dose Tricin group (Tricin 10 µM). All groups were treated for 48 h. The selection of Tricin doses was based on previous studies [11, 18]. Western blotting Cellular total proteins were extracted and quantified using the BCA detection kit (Beyotime Institute of Biotechnology, China). Following extraction, proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride (PVDF) membranes. After blocking with Tris‐buffered saline containing 0.05% Tween20 and 5% non-fat milk for 1.5 h, PVDF membranes were incubated with specific primary antibodies. The primary antibodies that used were MYD88 (1:5000, Proteintech, USA), NF-κB p65 (1:1000, Proteintech, USA), p- NF-κB p65 (1:1000, Abcam, USA), TLR4 (1:1000, Proteintech, USA) and β-actin (1:6000, Proteintech, USA). Immunoreactive bands were visualized using enhanced chemiluminescence (Bio‐Rad, USA) after incubation with horseradish peroxidase‐conjugated secondary antibodies. The protein levels were quantified using Image J analysis software version 1.38e and normalized to their respective controls. Fluorescence staining assay The production of reactive oxygen species (ROS) was measured using 2’,7’-dichlorofluorescein diacetate (DCFH-DA, Beyotime Institute of Biotechnology, China), following the manufacturer’s protocol. In brief, H9C2 cells were seeded into 6-well plates at a density of 1 × 104 cells per well. The cells were then incubated with 5 µM DCFH-DA for 30 min at 37 °C in the dark, then the cells were washed three times with PBS. After incubation, the fluorescence intensity of each group was measured using flow cytometry and subsequently analyzed. Detection of enzyme activities The activity of lactate dehydrogenase (LDH) and total superoxide dismutase (SOD) was measured using specific assay kits. LDH activity was determined using the LDH Activity Assay Kit (D799208, Sangon, China), and SOD activity was assessed using the Total Superoxide Dismutase Assay Kit with WST-8 (S0101S, Beyotime Institute of Biotechnology, China). All assays were performed according to the manufacturer’s instructions, and measurements were taken using a multifunctional microplate reader. Enzyme-Linked Immunosorbent Assay (ELISA) The cell culture medium was centrifuged at 2000 g for 5 min at 4 °C. The supernatant was then collected and stored at -20 °C until further experiments were conducted. The levels of IL-1β, IL-6, and TNF-α secreted by the treated and control group cells were quantified using commercial ELISA kits (R&D Systems, Minneapolis, MN, USA) following the manufacturer’s instructions. Statistical analysis Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA). The data were expressed as mean ± standard deviation (SD) from three independent experiments. Significant differences were determined using either one-way analysis of variance (ANOVA) or Student’s t-test, with a p-value of < 0.05 considered statistically significant. Results Tricin exhibits considerable safety in a DCM cell model To establish an in vitro cell model of diabetic cardiomyopathy (DCM), we treated H9C2 cells with varying concentrations of glucose. The results of the CCK-8 assay showed that cell viability of H9C2 cells decreased with increasing glucose concentrations, indicating the successful establishment of the DCM cell model (Fig. 1A). Based on these results, we selected a glucose concentration of 150 mM for subsequent experiments. Additionally, as shown in Fig. 1B, treatment with Tricin at specific concentrations did not significantly affect the viability of high glucose-induced H9C2 cells. This suggests that Tricin (at 1 µM, 2.5 µM, 5 µM, and 10 µM) demonstrates considerable safety in the application within the DCM cell model. The establishment of DCM cell model. (A) H9C2 cells were treated with different concentrations of glucose and cell viability was measured by CCK-8. *P < 0.05 vs. Control group, **P < 0.01 vs. Control group. (B) CCK8 experiment detected DCM model cells treated with different concentrations of Tricin. Data are presented as mean ± SD. *P < 0.05 vs. Control group, **P < 0.01 vs. Control group Tricin suppressed high glucose-induced oxidative stress In DCM, persistent hyperglycemia leads to mitochondrial dysfunction, resulting in the overproduction of reactive oxygen species (ROS). This excess ROS triggers oxidative stress, damaging cardiomyocytes and creating a vicious cycle. As shown in Fig. 2, ROS levels were significantly elevated in H9C2 cells in the high glucose-induced group, indicating severe oxidative stress in these cells. However, treatment with Tricin significantly mitigated the oxidative stress by reducing ROS levels. The extent of this inhibition was positively correlated with the concentration of Tricin. Tricin suppresses ROS production in DCM cell model. The intracellular ROS was detected with DCFH-DA and measured using flow cytometry. Data are presented as mean ± SD. ***P < 0.01 vs. Control group, ##P < 0.01 vs. HG group Tricin alleviates high glucose-Induced cellular damage and enhances antioxidant enzyme activity To further investigate the effects of Tricin on oxidative stress induced by high glucose, we evaluated the activities of both lactate dehydrogenase (LDH) and total superoxide dismutase (SOD). The results indicated that Tricin significantly alleviated the high glucose-induced increase in LDH levels (Fig. 3A) and the decrease in SOD levels (Fig. 3B) in H9C2 cells with a dose-dependent manner. Specifically, high glucose treatment led to a substantial rise in LDH activity, which is a marker of cellular damage and stress, while concurrently causing a notable reduction in SOD activity, an important antioxidant enzyme that protects cells from oxidative damage. This suggests that Tricin can effectively reduce cellular damage and bolster the antioxidant defense system in the presence of high glucose. Taken together, these findings highlight the protective effects of Tricin on both cellular damage and oxidative stress in the context of DCM, suggesting its potential therapeutic value in managing DCM. Effects of Tricin on LDH and SOD Levels in high glucose-Induced H9C2 cells. (A) LDH levels were measured to assess cellular damage. (B) SOD levels were measured to evaluate antioxidant enzyme activity. Data are presented as mean ± SD. **P < 0.01 vs. Control group, #P < 0.05 or ##P < 0.01 vs. HG group Anti-inflammatory effects of Tricin on DCM Cells Understanding the role of inflammation is crucial for studying DCM. To evaluate the anti-inflammatory effects of Tricin, we conducted ELISA experiments on high glucose-treated H9C2 cells. Based on the ELISA experiment results, Tricin treatment significantly inhibited the high glucose-induced elevation of TNF-α, IL-6, and IL-1β levels in H9C2 cells (Fig. 4A-C). The inhibitory effect of Tricin on these pro-inflammatory cytokines was found to be dose-dependent, with higher concentrations of Tricin leading to greater reductions in cytokine levels. These findings suggest that Tricin not only effectively mitigates high glucose-induced cellular damage and oxidative stress but also plays a crucial role in suppressing the expression of pro-inflammatory cytokines, thereby offering a multi-faceted protective effect in DCM. Tricin reduces high glucose-induced pro-inflammatory cytokine levels in H9C2 cells. ELISA results showing the effect of Tricin treatment on the levels of (A) TNF-α, (B) IL-6, and (C) IL-1β in H9C2 cells exposed to high glucose conditions. Data are expressed as mean ± SD. ***P < 0.01 vs. Control group, #P#x2009;< 0.05, ##P < 0.01 or ###P < 0.01 vs. HG group Inhibition of TLR4, MYD88, and p-NF-κB expression by Tricin in DCM To further explore the molecular mechanisms underlying the protective effects of Tricin, we conducted Western blot experiments to assess the expression levels of Toll-like receptor 4 (TLR4), MYD88, and p-nuclear factor (NF)-κB in H9C2 cells under high glucose conditions. The results demonstrated that high glucose treatment significantly elevated the protein expression of TLR4, MYD88, and p-NF-κB in H9C2 cells. However, Tricin treatment markedly inhibited the high glucose-induced increase in TLR4 and MYD88 protein expression as well as the activation of the NF-κB signaling pathway (Fig. 5). These findings suggest that Tricin can effectively suppress the inflammatory signaling pathways activated by high glucose, highlighting its potential therapeutic role in managing DCM. Tricin inhibits the expression of TLR4, MYD88, and p-NF-κB in high glucose-treated H9C2 cells. Western blot analysis showing the protein expression levels of TLR4, MYD88, and p-NF-κB in H9C2 cells exposed to high glucose conditions with or without Tricin treatment. Data are presented as mean ± SD. *p < 0.05, **p < 0.01 compared to the high glucose group without Tricin treatment. *P < 0.05 or **P < 0.01 vs. Control group, #P#x2009;< 0.05 or ##P < 0.01 vs. HG group Discussion Diabetes is a chronic disease that poses a severe threat to human health, with over 500 million adults affected worldwide [19]. Among the most common diabetes-related causes of death are cardiac complications. Diabetic cardiomyopathy (DCM) is characterized by progressively worsening heart failure symptoms, myocardial fibrosis, and impaired cardiac contractility. Despite being identified as early as 1972, the pathogenic characteristics of DCM remain undefined. Due to the multifaceted pathological mechanisms of DCM and its subtle early symptoms, there is currently no established therapy. While conventional antidiabetic treatments reduce the incidence of coronary events, they can occasionally exacerbate myocardial failure [20]. Recently, many flavonoid compounds have been found to act as natural epigenetic regulators, offering potential therapeutic effects in DCM, typically through anti-hyperglycemic, antioxidant, and anti-inflammatory processes [21, 22]. In this study, a DCM cell model was established using rat H9C2 cells, and it was discovered for the first time that the flavonoid compound Tricin (4’,5,7-trihydroxy-3‘,5’-dimethoxyflavone) significantly inhibits high glucose-induced oxidative stress, inflammatory responses, and the activation of the TLR4-MYD88-NF-κB signaling pathway. This study highlights the potential value of Tricin in the treatment of DCM. The balance between the production and degradation of reactive oxygen species (ROS), including superoxide anions, hydrogen peroxide, and hydroxyl radicals, determines the redox state within the body. When ROS levels become excessive, this state is defined as oxidative stress, which is a common phenomenon in DCM [23]. Persistent hyperglycemia leads to glucose auto-oxidation and oxidative degradation of glycated proteins, both contributing to excessive ROS production [24, 25]. Researchers have found that in the most typical type I diabetes animal models, the occurrence of myocardial diastolic and systolic dysfunction is closely related to elevated ROS levels [26]. This may be due to mitochondrial dysfunction induced by high glucose, which further triggers Ca2+ imbalance [27]. A substantial amount of research on preclinical trials has demonstrated the therapeutic benefits of antioxidants, including natural products, in reducing ROS levels in DCM [28, 29]. In this study, it was first discovered that Tricin is non-toxic to H9C2 cells and that dose-dependent Tricin significantly reduces high glucose-induced increases in ROS and LDH levels, as well as decreases in SOD levels, thereby alleviating oxidative stress in DCM. Similarly, Tricin, as a flavonoid compound, has been found to mitigate oxidative stress in diabetic retinopathy by promoting the expression of Sestrin 2, thereby protecting retinal epithelial cells [17]. Additionally, in models of pneumonia and acute colitis, Tricin has shown good safety profiles and has demonstrated its ability to alleviate oxidative stress by reducing MDA and nitric oxide production while increasing SOD levels [16, 30]. A cascade of pro-inflammatory reactions can lead to myocardial cell death, fibrosis, and hypertrophy in DCM, making it a significant factor, alongside oxidative stress, in the onset and progression of the disease [31]. Under DCM conditions, the excessive release of pro-inflammatory molecules such as TNF-α, IL-1β, and IL-6 exacerbates the activation and recruitment of leukocytes, further contributing to cardiac damage [32]. Given that flavonoids exhibit remarkable anti-inflammatory effects, a growing number of studies have begun to explore their potential benefits in DCM. For instance, galangin has been shown to protect the myocardium in DCM rat models by scavenging free radicals and reducing levels of pro-inflammatory factors [33]. Wogonin, a compound that has been confirmed to possess safety for intravenous administration, also showed potential therapeutic value in DCM through its anti-inflammatory property [34]. In our study, we have identified for the first time that Tricin treatment significantly alleviates the high glucose-induced elevation of TNF-α, IL-1β, and IL-6 levels in H9C2 cells, highlighting its anti-inflammatory potential in DCM. Similarly, Tricin has been demonstrated to inhibit inflammation and brain injury induced by ischemia-reperfusion through the activation of the PI3K/Akt signaling pathway [35]. Furthermore, in the classical LPS-induced hPBMCs inflammation model, Tricin significantly suppressed the activation of TNF-α and IFN-γ, thereby mitigating the inflammatory response and protecting against endothelial injury [36]. Toll-like receptor 4 (TLR4)/nuclear factor (NF)-κB signaling pathway overactivation is closely associated with the progression of DCM. In DCM, high glucose levels stimulate myocardial cells, leading to an increased expression of TLR4 ligands on the cell membrane. This activation subsequently triggers the MyD88-dependent pathway, promoting the expression of pro-inflammatory cytokines and chemokines [37]. These cytokines not only perpetuate the inflammatory response but also contribute to the production of additional ROS, creating a vicious cycle of inflammation and oxidative stress [38]. Flavonoid compound fisetin has been shown to alleviate kidney inflammation and apoptosis in sepsis-induced acute kidney injury by inhibiting the activity of the NF-κB and MAPK signaling pathways [39]. Myricetin can alleviate allergic symptoms in both in vivo and in vitro models of atopic dermatitis in mice by blocking the NF-κB and STAT1 signaling pathways, thereby downregulating the expression of thymus and activation regulated chemokine [40]. In our study, treatment with Tricin effectively inhibited the high glucose-induced upregulation of TLR4, MYD88, and p-NF-κB in a dose-dependent manner. These findings suggest that Tricin can modulate this key inflammatory pathway and potentially mitigate inflammation-induced cardiac damage in DCM. Additionally, other studies have shown that Tricin can interfere with TLR4 activation, blocking the upstream activation cascade of MYD88 and TRIF proteins, thereby inhibiting NF-κB signaling and exerting anti-inflammatory effects [15]. A previous studiy in LPS-induced inflammation model have demonstrated that Tricin directly targets key inflammatory signaling pathways like NF-κB and MAPK, suggesting that Tricin’s anti-inflammatory effects could be a primary cause rather than a secondary consequence of other cellular changes [36]. While our findings support a direct anti-inflammatory mechanism, further studies are necessary to definitively establish whether Tricin’s impact on inflammation is the cause or the result of broader cellular changes. Tricin has shown promising biological activity in various in vivo studies as well. For example, in a rat model of male infertility, Tricin significantly increased reproductive hormones such as testosterone, luteinizing hormone, follicle-stimulating hormone, and prolactin, while lowering DHEA-SO4 levels, suggesting its potential therapeutic role in treating infertility [41]. Tricin 7-glucoside has been shown to protect the brain from ischemia-reperfusion injury in vivo by blocking TNF-α-induced NF-κB and IκB-α phosphorylation, which in turn reduces brain damage and mitigates blood-brain barrier disruption. Additionally, this compound exhibits a favorable therapeutic window and demonstrates significant neuroprotective activity, even when administered with delayed timing [42]. Although clinical applications of Tricin have yet to be explored, it has displayed excellent pharmacokinetics and bioactivity in preclinical studies. Methylated flavonoids, including Tricin, are known for their high oral bioavailability and therapeutic potential [43]. These findings, along with the current study’s results, highlight Tricin’s potential as a promising candidate for managing DCM. In conclusion, this study demonstrates that Tricin exhibits good safety in DCM model cells and can mitigate the increase in ROS and LDH levels as well as the decrease in SOD levels induced by high glucose, thereby alleviating oxidative stress. Additionally, Tricin was found to reduce the high glucose-induced elevation of TNF-α, IL-1β, and IL-6, as well as the overactivation of the TLR4-MYD88-NF-κB signaling pathway, thus attenuating the inflammatory response. These results provide valuable insights into the potential mechanisms through which Tricin can protect against high glucose-induced cardiac damage and underscore its therapeutic promise in DCM treatment. However, it should be noted that this study’s findings are based on cell experiments, and further in vivo studies are needed to confirm Tricin’s efficacy and safety in living organisms. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Not applicable. Author contributions Rong Yu designed and performed the research and wrote the paper; Yaping Zhang and Tong Wang contributed to the data analysis and literature research; Jinju Duan organized the materials and contributed to Statistical analysis; Xiaoming Li guided and supervised the research. All authors reviewed and approved the final manuscript. Funding This work was supported by Shanxi Province Traditional Chinese Medicine Research Topic (No. 2023ZYYC2040). Data availability The raw data supporting the conclusions of this article will be made available by the authors without undue reservation. Declarations Ethics approval and consent to participate Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The raw data supporting the conclusions of this article will be made available by the authors without undue reservation.